Enovis (NYSE:ENOV) Trading Down 7.1% – What’s Next?

Enovis Corporation (NYSE:ENOV)’s share price fell 7.1% during mid-day trading on Wednesday . The stock traded as low as $23.67 and last traded at $23.70. Approximately 441,065 shares were traded during trading, a decline of 59% from the average session volume of 1,084,874 shares. The stock had previously closed at $25.52.

Wall Street Analyst Weigh In

ENOV has been the subject of a number of research reports. Evercore set a $32.00 target price on shares of Enovis in a report on Monday. Wells Fargo & Company dropped their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Zacks Research downgraded shares of Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.83.

Enovis Stock Performance

The stock’s 50 day moving average price is $23.32 and its two-hundred day moving average price is $23.83. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -1.19 and a beta of 1.39.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts forecast that Enovis Corporation will post 3.12 EPS for the current year.

Insider Buying and Selling

In other news, insider Oliver Engert bought 1,200 shares of the stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired 4,200 shares of company stock worth $92,084 in the last quarter. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently made changes to their positions in ENOV. California State Teachers Retirement System grew its position in shares of Enovis by 1.2% in the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after purchasing an additional 621 shares during the last quarter. MGO One Seven LLC lifted its position in shares of Enovis by 9.4% in the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock valued at $202,000 after acquiring an additional 650 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares in the last quarter. Empowered Funds LLC raised its stake in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares during the last quarter. Finally, Inscription Capital LLC raised its stake in Enovis by 9.4% in the 4th quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock valued at $316,000 after purchasing an additional 1,016 shares during the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.